Media coverage about Taro Pharmaceutical Industries (NYSE:TARO) has trended somewhat positive recently, according to Accern. The research group scores the sentiment of press coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Taro Pharmaceutical Industries earned a coverage optimism score of 0.12 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 46.5611819998193 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Taro Pharmaceutical Industries opened at $119.85 on Thursday, MarketBeat.com reports. The company has a market cap of $4.78 billion, a PE ratio of 19.39 and a beta of 0.67. Taro Pharmaceutical Industries has a 1-year low of $93.01 and a 1-year high of $128.46.
Taro Pharmaceutical Industries (NYSE:TARO) last issued its quarterly earnings results on Thursday, May 17th. The company reported $2.17 EPS for the quarter, topping the consensus estimate of $1.51 by $0.66. The company had revenue of $175.22 million during the quarter, compared to analyst estimates of $166.59 million. Taro Pharmaceutical Industries had a net margin of 31.90% and a return on equity of 11.33%. sell-side analysts anticipate that Taro Pharmaceutical Industries will post 9.67 earnings per share for the current year.
Several equities analysts have recently weighed in on the stock. HC Wainwright set a $130.00 target price on shares of Taro Pharmaceutical Industries and gave the company a “buy” rating in a report on Tuesday, May 22nd. Zacks Investment Research raised shares of Taro Pharmaceutical Industries from a “hold” rating to a “buy” rating and set a $129.00 target price for the company in a report on Saturday, May 26th. ValuEngine raised shares of Taro Pharmaceutical Industries from a “sell” rating to a “hold” rating in a report on Wednesday, March 14th. Finally, TheStreet raised shares of Taro Pharmaceutical Industries from a “c+” rating to a “b-” rating in a report on Monday, June 4th. Two equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $129.50.
About Taro Pharmaceutical Industries
Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, engages in the development, manufacture, and marketing of pharmaceutical products in the United States, Canada, Israel, and internationally. It offers prescription and over-the-counter pharmaceutical products focusing on primary areas, including topical creams and ointments, liquids, capsules, and tablets in the dermatological and topical, cardiovascular, neuropsychiatric, and anti-inflammatory therapeutic categories.
Receive News & Ratings for Taro Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taro Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.